Antiplatelet drugs overview
College of Pharmacy, Al-Nahrain University, Iraq.
Review Article
GSC Biological and Pharmaceutical Sciences, 2020, 10(01), 081-089.
Article DOI: 10.30574/gscbps.2020.10.1.0003
Publication history:
Received on 07 January 2020; revised on 15 January 2020; accepted on 19 January 2020
Abstract:
Platelets are essential factor in the pathophysiology of atherothrombosis, abnormal platelet function guiding to many cardiovascular complications such as myocardial infarction and ischemic stroke. There are numerous antiplatelet drugs approved for use in the clinical management and several under examination. Antiplatelet drugs with the high potency are mostly associated with the intensifying incidence of bleeding. Aspirin and clopidogrel (alone or dual) are the mostly used drugs with the best favorable risk-benefit profiles of drugs available. While cangrelor and ticagrelor may produce further benefits but need more studies .Other drugs such as prasugrel, dipyridamole and cilostazol are not widely used.
Keywords:
Aspirin; Thienopyridines; Coronary heart disease
Full text article in PDF:
Copyright information:
Copyright © 2020 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
